Mycobacterium abscessus pulmonary disease
Conditions
Brief summary
Negative MABS cultures from four consecutive sputum samples with one of those sputum specimens collected four weeks after the completion of consolidation therapy, or a MABS negative Bronchoalveolar Lavage (BAL) collected four weeks after completion of consolidation., “Good” tolerance is defined as no adverse events occurring or only adverse events coded as CTCAE grades 1 and 2. “Poor” tolerance is defined as any adverse events attributed as possibly-, probably-, or definitely-related to study drug coded as CTCAE grades 3, 4, or 5.
Interventions
DRUGLINEZOLID
DRUGDOXYCYCLINE
DRUGCEFOXITIN
DRUGCLARITHROMYCIN
DRUGMOXIFLOXACIN
DRUGAMIKACIN
DRUGIMIPENEM
DRUGCLOFAZIMINE
DRUGRIFABUTIN
DRUGCILASTATIN
DRUGTRIMETHOPRIM
DRUGAZITHROMYCIN
DRUGTIGECYCLINE
DRUGETHAMBUTOL
DRUGSULFAMETHOXAZOLE
DRUGBEDAQUILINE
Sponsors
The University Of Queensland
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Negative MABS cultures from four consecutive sputum samples with one of those sputum specimens collected four weeks after the completion of consolidation therapy, or a MABS negative Bronchoalveolar Lavage (BAL) collected four weeks after completion of consolidation., “Good” tolerance is defined as no adverse events occurring or only adverse events coded as CTCAE grades 1 and 2. “Poor” tolerance is defined as any adverse events attributed as possibly-, probably-, or definitely-related to study drug coded as CTCAE grades 3, 4, or 5. | — |
Countries
Denmark
Outcome results
None listed